Literature DB >> 6300497

Antigenic heterogeneity of human lung cancers.

A Harłozińska, R Richter, Z Albert, H Zawadzka.   

Abstract

Antigenic reactivity of 35 perchloric acid (PCA) extracts of different histologic human lung cancer tissues was studied--in comparison with the reactivity of the carcinoembryonic antigen (CEA), the nonspecific cross-reacting antigen (NCA), and alpha-1-antichymotrypsin--with the use of specific immune sera against PCA extracts of lung squamous cell carcinoma, and anti-CEA, anti-NCA, and anti-alpha-1-antichymotrypsin sera. The following antigenic systems were found in lung cancers: a) antigens specific for most squamous cell cancers and adenocarcinomas, which are undetectable in small cell cancers; b) NCA-type antigens; c) CEA-like antigens; and d) the antigen responsible for alpha-1-antichymotrypsin reactivity. A considerable antigenic heterogeneity among lung cancers indicates the necessity for precise histopathologic verification of individual lung cancer cases before commencement of immunologic studies and purification of antigens specific for lung cancers.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300497

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  3 in total

1.  Characterization of prostate-tissue-directed monoclonal antibody, alpha-Pro 13.

Authors:  K S Webb; D F Paulson; S F Parks; F L Tuck; P J Walther; J L Ware
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  A monoclonal antibody (Po66) directed against human lung squamous cell carcinoma immunolocalization of tumour xenografts in nude mice.

Authors:  L Dazord; D Bourel; A Martin; R Lecorre; P Bourguet; J Bohy; J C Saccavini; P Delaval; M Louvet; L Toujas
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series.

Authors:  A Noworolska; A Harłozińska; R Richter; W Brodzka
Journal:  Br J Cancer       Date:  1985-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.